Semax: BDNF Upregulation and Neuroprotection Research

# Semax: BDNF Upregulation and Neuroprotection Research

For Research Purposes Only — Not Intended for Human or Animal Consumption

Introduction

Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is a synthetic heptapeptide derived from the N-terminal fragment of adrenocorticotropic hormone (ACTH 4-7), extended with the sequence Pro-Gly-Pro to improve metabolic stability. It was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences and has been registered as a pharmaceutical in Russia for the treatment of stroke, transient ischemic attacks, and cognitive impairment.

The published research on Semax is more extensive than most research peptides, including both mechanistic preclinical studies and clinical trials, with a particular focus on neuroprotection and cognitive enhancement.

BDNF Upregulation: The Primary Mechanism

The most consistently documented effect of Semax is upregulation of brain-derived neurotrophic factor (BDNF) and its receptor, TrkB. BDNF is a neurotrophin that promotes neuronal survival, axonal growth, synaptic plasticity, and hippocampal neurogenesis. It is considered one of the most important molecules for learning, memory, and neuroprotection.

Dolotov et al. (2006) demonstrated that intranasal Semax administration produced a rapid and sustained increase in BDNF mRNA expression in the rat hippocampus and frontal cortex — brain regions critical for memory formation and executive function. The BDNF increase was accompanied by upregulation of TrkB receptor expression, amplifying the downstream signaling response.

Subsequent research confirmed that Semax-induced BDNF upregulation activates downstream signaling cascades including the MAPK/ERK pathway and PI3K/Akt pathway — both of which promote neuronal survival and synaptic strengthening.

Neuroprotection in Ischemia Models

Semax has been extensively studied in models of cerebral ischemia — the primary application for which it is registered as a pharmaceutical in Russia. Ischemia produces neuronal death through multiple mechanisms including excitotoxicity (excessive glutamate signaling), oxidative stress, and inflammation.

Kost et al. (2001) demonstrated that Semax administration following experimental stroke in rats significantly reduced the volume of infarcted tissue and improved neurological outcomes. The neuroprotective effects were associated with reduced expression of inflammatory cytokines and decreased oxidative damage markers in the ischemic penumbra — the region of brain tissue at risk but not yet irreversibly damaged.

Grivennikov et al. (2008) proposed that Semax's neuroprotective effects are mediated primarily through BDNF upregulation, which activates anti-apoptotic signaling and enhances the survival of neurons in the ischemic penumbra.

Cognitive Enhancement Research

Beyond neuroprotection, Semax has been studied for cognitive enhancement in both animal models and clinical populations. The proposed mechanism involves BDNF-mediated enhancement of synaptic plasticity — specifically long-term potentiation (LTP), the cellular correlate of memory formation.

Vanhanen et al. (2001) demonstrated that Semax improved performance on spatial memory tasks in rats, with effects comparable to established nootropic compounds. The cognitive enhancement was blocked by TrkB antagonists, confirming BDNF receptor dependence.

Clinical studies in Russia have examined Semax in patients with cognitive impairment following stroke and in healthy subjects. Reported effects include improvements in attention, working memory, and processing speed, though these studies have methodological limitations including small sample sizes and lack of independent replication.

Melanocortin Receptor Activity

Semax's parent sequence (ACTH 4-7) has affinity for melanocortin receptors, particularly MC4R — a receptor expressed throughout the brain that modulates learning, memory, and neuroprotection. Some of Semax's cognitive effects may be mediated through melanocortin receptor activation in addition to BDNF upregulation.

The MC4R pathway is distinct from the BDNF/TrkB pathway and may contribute independently to Semax's cognitive profile. This dual mechanism — melanocortin receptor activation plus BDNF upregulation — may explain the breadth of cognitive effects reported in the literature.

References

1. Dolotov, O.V., et al. (2006). Semax, an analogue of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Research, 1117(1), 54–60.
2. Kost, N.V., et al. (2001). Semax and selank inhibit the enkephalin-degrading enzymes from human serum. Bioorganicheskaya Khimiya, 27(3), 180–183.
3. Grivennikov, I.A., et al. (2008). Behavioral effects and c-Fos expression in rats following administration of Semax. Peptides, 29(11), 1965–1971.